Research progress on the role and mechanism of S100A8/S100A9 in retinal degenerative diseases

Autor: Huang Weidi, Lu Caiyang, Chen Shuming, Tang Zichun, Li Xie, Zheng Shuyan, Huang Xixuan, Liu Xiao, Li Zhuo

Publikováno v: Guoji Yanke Zazhi, Vol 24, Iss 10, Pp 1610-1614 (2024)

The S100 protein family is a key component of damage-associated molecular patterns(DAMP), which play a vital role in regulating inflammation in the body's innate immune response. S100A8/S100A9 proteins play a wide range of antibacterial and anti-infe

Externí odkaz: https://doaj.org/article/e6eb6795df1d40de8e2badbf68ac1754

Machine learning and single-cell RNA sequencing reveal relationship between intratumor CD8 ⁺ T cells and uveal melanoma metastasis.

Autor: Chen S; Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.; Hunan Clinical Research Center of Ophthalmic Disease, Changsha, Hunan, 410011, China., Tang Z; Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.; Hunan Clinical Research Center of Ophthalmic Disease, Changsha, Hunan, 410011, China., Wan Q; Department of Anaesthesiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China., Huang W; Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.; Hunan Clinical Research Center of Ophthalmic Disease, Changsha, Hunan, 410011, China., Li X; Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.; Hunan Clinical Research Center of Ophthalmic Disease, Changsha, Hunan, 410011, China., Huang X; Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.; Hunan Clinical Research Center of Ophthalmic Disease, Changsha, Hunan, 410011, China., Zheng S; Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.; Hunan Clinical Research Center of Ophthalmic Disease, Changsha, Hunan, 410011, China., Lu C; Hunan Centre for Drug Review and Adverse Reaction Monitoring, Changsha, Hunan, 410013, China., Wu J; Hunan Provincial Drug Administration, Changsha, Hunan, 410013, China., Li Z; Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. LiZhuo75@csu.edu.cn.; Hunan Provincial Key Laboratory of Critical Quality Attribute of Cell Therapy Products, Changsha, Hunan, 410013, China. LiZhuo75@csu.edu.cn., Liu X; Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. Liuxiao8@csu.edu.cn.; Hunan Clinical Research Center of Ophthalmic Disease, Changsha, Hunan, 410011, China. Liuxiao8@csu.edu.cn.

Publikováno v: Cancer cell international [Cancer Cell Int] 2024 Oct 30; Vol. 24 (1), pp. 359. Date of Electronic Publication: 2024 Oct 30.